

## REVIEW ARTICLE

# Suppressive drug combinations and their potential to combat antibiotic resistance

Nina Singh and Pamela J Yeh

**Antibiotic effectiveness often changes when two or more such drugs are administered simultaneously and unearthing antibiotic combinations with enhanced efficacy (synergy) has been a longstanding clinical goal. However, antibiotic resistance, which undermines individual drugs, threatens such combined treatments. Remarkably, it has emerged that antibiotic combinations whose combined effect is lower than that of at least one of the individual drugs can slow or even reverse the evolution of resistance. We synthesize and review studies of such so-called ‘suppressive interactions’ in the literature. We examine why these interactions have been largely disregarded in the past, the strategies used to identify them, their mechanistic basis, demonstrations of their potential to reverse the evolution of resistance and arguments for and against using them in clinical treatment. We suggest future directions for research on these interactions, aiming to expand the basic body of knowledge on suppression and to determine the applicability of suppressive interactions in the clinic.**

*The Journal of Antibiotics* (2017) **70**, 1033–1042; doi:10.1038/ja.2017.102; published online 6 September 2017


Since the clinical introduction of penicillin in the 1940s, bacterial resistance to nearly all antibiotics has evolved and spread, presenting a serious threat to human health.<sup>1–3</sup> Clinicians have treated resistant strains with ever higher doses of antibiotics,<sup>2,3</sup> often resulting in the evolution of bacteria capable of tolerating antibiotic levels exceeding those safe for the patient. In certain cases, major pathogens such as extensively drug resistant tuberculosis (TB) have developed resistance to virtually every effective antibiotic regime.<sup>4</sup> To combat this impending crisis, researchers have focused on identifying antibiotic classes with novel cellular and metabolic targets,<sup>5</sup> modifications to existing drugs that restore effectiveness against resistant bacteria<sup>6</sup> and co-administered chemical agents that disable specific drug resistance mechanisms,<sup>7,8</sup> increase antibiotic bioavailability<sup>9</sup> or decrease toxicity of high dosages to the patient.<sup>10</sup> Researchers and clinicians have additionally taken into account physiological changes in patients that affect antibiotic concentrations and bacterial susceptibility (sensitivity), in order to maximize the effectiveness of antibiotics through individualized antibiotic dosing.<sup>11</sup>

These methods are designed to restore our capacity to treat resistant bacterial infections, but they often rely on fighting a traditional evolutionary ‘arms race’ against the pathogens, where new antibiotic compounds are discovered and introduced as quickly as those in service are made obsolete by the spread of resistance. Given the decreasing discovery rates of novel antibiotics,<sup>12</sup> the proven bacterial capacity to develop and disseminate novel resistance mechanisms<sup>13</sup> and the widespread exposure of bacteria to antibiotics in clinical and agricultural contexts,<sup>14</sup> we do not expect to win this arms race.

Preserving the future efficacy of antibiotics therefore requires active reduction or even reversal of the selection that favors antibiotic resistance in the (necessary) presence of antibiotics. Indeed, various approaches to this goal are being explored.<sup>15</sup> For instance, policy controls on antibiotic use in agriculture and their periodic removal from clinical use are aimed at reducing unnecessary selection for resistance,<sup>16</sup> whereas screens for non-antibiotic compounds that target particular resistance mechanisms aim to eliminate them by increasing the cost of their carriage.<sup>8,17</sup>

Strategies to combat resistance that employ drugs in combination have emerged as effective therapies since at least the 1940s<sup>18</sup> and include important combinations used to combat HIV, TB and, to some degree, cancer.<sup>19–21</sup> The range of organisms targeted by different antimicrobial compounds, as well as the considerable differences between the combined and individual effects of these drugs, have resulted in much research and clinical effort directed at identifying drug combinations that most effectively kill the widest range of pathogens.<sup>22,23</sup>

Research on identifying and classifying drug combinations has been conducted both in the form of large screens<sup>20,24,25</sup> and in specific studies focused mainly on synergistic combinations.<sup>26</sup> Although certain such combinations of compounds are more powerful together than predicted from their individual effects (termed synergistic interactions), the combined effects of others do not differ substantially from predicted effects (additive drug interactions). Yet others exhibit less inhibition than expected based upon their individual effects (antagonistic interactions). Among the set of antagonistic interactions, there exists a curious subset of drug combinations in which the joint



**Figure 1** Schematic representation of suppressive drug interactions: single concentrations and gradients. Here we show suppressive drug interactions in two-drug and three-drug combinations, in both single concentrations per drug and gradients of drugs. The two most widely used systems for classifying drug interactions are Loewe additivity<sup>108</sup> and Bliss independence.<sup>28</sup> Loewe additivity relies on entire gradients of each drug, whereas Bliss independence categorizes drug interactions based on single-point concentrations per drug. Two-drug combinations: (a and b) Loewe and Bliss differ in how they define additivity. Loewe defines additive drugs as those whose inhibition is constant along lines of equal effective dosage in a two-drug concentration graph. In this case, isoboles (lines of constant inhibition) can be plotted based on data for two drugs across a range of dosages. Following previous papers,<sup>29,35,44</sup> in a the non-monotonic concave isobole (red) defines synergy, the monotonic linear isobole (orange) defines additivity, the non-monotonic convex isobole (green) defines antagonism and the non-monotonic isobole with even greater convexity (blue) defines suppression. (Note that this is a simplified depiction, as isoboles indicating suppression are often non-monotonic.<sup>35</sup>) Bliss defines additivity as the result when the relative effect of a drug at a certain concentration is independent of the presence of the other drug. If Drug X and Drug Y are additive, then  $w_{XY} = w_X w_Y$ , where  $w$  is relative fitness. Suppression occurs when the combined effect of two drugs is less than the effect of one or both (b) of the drugs. In b, any growth response caused by Drug X + Drug Y that is above the dotted line indicates that Drug X and Drug Y are suppressive. Three-drug combinations: (c, d) Recently these systems have been extended to classify higher-order drug interactions. Interactions are considered suppressive if the combined effect of the three drugs is less than the effect of any of the pairwise combinations or the single drugs.<sup>53</sup> Loewe's extension to three drugs is shown in c and suppression is characterized by an increase in growth (fitness) when all three drugs are present in high concentration. Growth response (fitness) increases as the combination becomes more suppressive (where red is synergistic, orange is additive, green is antagonistic and blue is suppressive), as shown by the increasing convexity on the surfaces. In d, Bliss's extension to three drugs is shown. Any growth rate caused by Drug X + Drug Y + Drug Z that is above either dotted line (one for the highest single drug growth response (black) and one for the highest pairwise drug growth response (green)) indicates reciprocal suppression.

inhibitory effect of two drugs is even less than the effect of one or both of the compounds, alone. So-called 'suppressive' interactions can be directional (the joint effect is reduced below that of one of the drugs) or reciprocal (the combination is less inhibitory than either individual component) (Figure 1). In order to understand, classify and screen for different interactions, much effort has gone into establishing formal classification schemes (summarized in ref. 27). These schemes typically capture many but not all aspects of such interactions and have usually not highlighted suppressive interactions.<sup>28</sup>

Recently, certain suppressive interactions between antibiotics administered in combination have been observed to select for susceptibility over resistance to the individual component drugs.<sup>29</sup> Intriguingly, the increased cost of resistance over susceptibility imposed by the drug combination appears largely independent of the allele or even exact mechanism of resistance. This selection reversal occurs in the presence of susceptible and resistant bacterial populations, suggesting that suppressive antibiotic combinations might provide unusual antibiotic treatments, which simultaneously treat infections while guarding against evolution of resistance.

In this review, we examine the suppressive interaction, its characterization and the mechanisms of its effects on selection. We consider why it has been largely unappreciated despite identification well over a century ago, debate its potential for clinical applications

and suggest next steps for the investigation of these unusual interactions.

## A BIAS AGAINST SEARCHING FOR AND REPORTING SUPPRESSIVE INTERACTIONS

A study published by Fraser<sup>30</sup> is the first account of suppression in the literature. Working at a time when powerful modern tools of screening detection were unavailable, Fraser<sup>30</sup> noted that when rabbits were injected with physostigmine, a cholinesterase inhibitor produced by *Physostigma venenosum*, within 20–30 minutes, it became difficult to 'distinguish any respiratory movement or cardiac impulse [in the rabbit], and they soon altogether cease on the occurrence of death.' However, when the rabbits were injected with atropine subsequent to the same dose of physostigmine, they survived. Fraser<sup>30</sup> termed this interaction between the drugs a "physiological antidote," to stress that the source of the effect is an interaction between the physiological responses of the rabbit to the drugs in combination and not a purely chemical interaction between the compounds alone: "When... among the different counteracting actions that occur in general antagonism, there are included any by which the fatal effect of one or other of the substances is usually produced, the one substance may act towards the other as a physiological antidote."<sup>30,31</sup>

Fraser<sup>31</sup> anticipated that many more studies of suppressive drug interactions would follow his publications, but these were few and far between for the next 100 years. Although the study received contemporary attention and a few scientists followed up on Fraser's research,<sup>26,32–34</sup> investigations of the suppressive interaction have been largely absent until this past decade. Indeed, an exhaustive search of the works citing Fraser found that the overwhelming majority of citations were for his development of the isobole method of representing drug interactions, with remarkably few papers even mentioning his work on suppressive interactions. An increase in acknowledgements of this work has occurred during the past decade,<sup>35–38</sup> with renewed interest in suppressive interactions, particularly to treat antibiotic resistant bacteria. A recently increased focus on the effects of antibiotic combinations on bacteria and new high-throughput measurement technology have enabled more accurate classification and screening of antibiotic suppression,<sup>24,29,35,39–43</sup> and an increasing number of researchers have been drawn to the question of suppression.<sup>25,29,44–47</sup> Finally, the potential of suppressive combinations to counter the evolution of antibiotic resistance<sup>29,39,48</sup> has spurred additional interest in this topic.

The surprisingly few references to suppression in the literature are not limited to works citing Fraser. There is a significant bias against reporting antagonistic interactions (and especially suppressive interactions, which are often classified more broadly as antagonistic interactions when reported).<sup>25,49–52</sup> When comparing a database of interactions between antibiotics generated by manually curating Pubmed literature on *in vitro* antibiotic interaction experiments<sup>35</sup> with a complete pairwise interaction network for 21 antibiotics<sup>24</sup> and a complete 3-way interaction network for 14 antibiotics,<sup>53</sup> the database of literature-curated interactions had significantly more synergy and less antagonism in both cases ( $P$ -value < 0.001). In studies with smaller numbers of drug–drug combinations, no suppressive interactions were found out of 10 total interactions<sup>54</sup> and 2 suppressive interactions were found out of 30 total interactions.<sup>55</sup> However,


the discrepancy in proportions of antagonism and suppression between the literature-curated data and the whole network analyses suggest an under-representation of the discovery and reporting of these interactions (Figure 2).

Other researchers have found similar biases against reporting antagonistic and specifically suppressive interactions.<sup>49–52,56</sup> The most obvious explanation for this bias is that screens for antibiotic interactions typically have clinical applications in mind, and have targeted synergistically interacting drugs. From a traditional, clinical viewpoint, treatments that require higher drug concentrations to achieve the same or lower degree of pathogen inhibition would appear to make little sense,<sup>57</sup> as higher levels of antibiotics are more likely to adversely affect patients<sup>26,58</sup> and increase costs. Therefore, although suppressive combinations have the potential to reverse evolution of antibiotic resistance, to the best of our knowledge, no *in vivo* studies on suppressive drug combinations have been conducted.

Other reasons may also factor into the underrepresentation of antagonistic and suppressive combinations in the literature. The many different experimental methods for determining drug interactions and interaction classification schemes (see review in Fouquier and Guedj<sup>27</sup>) can be confusing and result in varying levels of rigor,<sup>56</sup> leading authors to overlook antagonistic results.<sup>49</sup> For example, Bliss independence assumes that non-interacting toxins are completely independent of each other in their effects, so a drug can 'interact' with itself, making classifications harder to interpret. Furthermore, as Bliss independence only requires four measurements of bacterial growth (in the absence of either drug, in the presence of drug A alone, drug B alone, and drug A and B together), the classification method may not adequately represent the different types of interactions drugs can demonstrate when measured under different sets of concentrations. Although Loewe additivity rectifies the concentration issue by requiring measurements of growth rates over a two-dimensional field of pairwise dosages of each of the individual drugs, this can be extremely logistically challenging (Figure 1). However, mathematical solutions to Loewe additivity exist, allowing approximations to be obtained from fewer measurements.<sup>59</sup>

Variability in specific thresholds used for classification of an interaction and in the precision of the technology used to measure the interaction can also contribute to biases against reporting antagonistic results. Other factors such as genetic variations, environmental factors, host behavior<sup>56</sup> and isolate-specific interactions<sup>60,61</sup> may further affect the classification of drug interactions and could lead to the misreporting of antagonistic interactions. In particular, a drug combination can be antagonistic over one concentration range and synergistic over another. When interactions are not measured in two-dimensional concentration gradients, it becomes possible to report a combination as synergistic when it has the potential to be antagonistic or even suppressive.<sup>62</sup>

The underreporting of suppressive drug interactions is likely to diminish with the emergence of new technologies that allow for larger and less biased screens.<sup>24,29,35,39–43</sup> Ideally, more concentrations should be tested to detect concentration dependencies and enable researchers and clinicians to better understand the magnitude of interactions being reported. We suggest that it is important to search for and correctly identify suppressive drug combinations from both academic and clinical perspectives, as suppression is a distinct type of interaction with unique properties and consequences, including the potential to slow and even reverse the evolution of resistance.



**Figure 2** Bias towards synergy in a literature-curated database of two-antibiotic combinations. In a database of interactions between antibiotics based on manually curated Pubmed literature on *in vitro* antibiotic interaction experiments,<sup>35</sup> 61% of interactions were synergistic and 39% were antagonistic or suppressive. When a complete two-drug interaction network was studied using 21 drugs, 42% of drug interactions were synergistic and 58% were antagonistic or suppressive ( $\chi^2$ ,  $P$ -value < 0.001).<sup>24</sup> When a complete three-drug interaction network was studied using 14 drugs, 23% of interactions were synergistic and 77% were antagonistic or suppressive ( $\chi^2$ ,  $P$ -value < 0.001).<sup>53</sup> In the three-drug interaction data set, the interactions measured were 'emergent' interactions, meaning that these interactions were categorized based on deviations from all two-drug components. Inconclusive and additive cases were excluded when calculating proportions for all data sets.


### SUPPRESSIVE DRUG COMBINATIONS AND THEIR POTENTIAL TO SLOW OR REVERSE EVOLUTION OF RESISTANCE

Although it has been shown that antagonistic interactions can reduce the selective advantage of antibiotic resistant strains over susceptible ones,<sup>29,39</sup> only suppressive interactions can fully reverse this selective advantage.<sup>15</sup> Suppressive antibiotic combinations can allow antibiotic susceptible bacteria to out-compete bacteria that are resistant to one of the drugs in a two-drug treatment (Figure 3), as illustrated in Chait *et al.*<sup>29</sup>

To demonstrate this potential, drug-susceptible bacteria and doxycycline-resistant mutants were assigned to grow under two different drug pairings: a synergistic combination of doxycycline and erythromycin or a suppressive combination of doxycycline and ciprofloxacin. In the synergistic drug combination, the doxycycline-resistant bacteria appeared to gain relief both from doxycycline itself and from the additional inhibitory effect of the synergy with erythromycin; it handily outcompeted the susceptible bacteria. However, at various concentrations of the antibiotics in the suppressive drug combination, the benefit of resistance to doxycycline was outweighed by the associated loss of its protection from ciprofloxacin. In these regimes, the doxycycline-susceptible bacteria outcompeted the doxycycline-resistant strain, despite the presence of the resisted drug.<sup>29</sup>

Herein there is a potential concept for clinical translation: over time, resistant bacteria can be outcompeted by more susceptible strains, leaving a population of drug-susceptible, treatable bacteria that would be more susceptible to classical antibiotics or synergistic combinations. Particular drug environments can generate local fitness peaks where greater relative fitness actually requires drug susceptibility instead of resistance. Although under synergistic combinations bacteria always increase in fitness if they can gain resistance to one or more drugs, in the case of suppressive drug environments, if a bacterium gains resistance to one drug, its fitness may decrease. Selection could therefore constrain populations to a local fitness peak dominated by bacteria that are susceptible to certain antibiotics.<sup>29</sup>

Resistance mutations often impose fitness costs that favor susceptible over resistant bacteria at very low or no drug concentrations. Secondary, compensatory mutations that reduce these costs frequently



**Figure 3** How suppressive drug combinations can leave drug-space for wild-type bacteria to outcompete resistant mutants. Synergistically interacting drugs amplify each others' effects (left panel), whereas a drug in a suppressive pair cancels the effect of the other (right panel). Black lines outline minimum inhibitory isoboles for antibiotic X-susceptible ( $X^S$ ) bacteria in combinations of drugs X and Y. X-resistance ( $X^R$ ) reduces effective concentrations of the antibiotic X, producing isoboles and a growth region that are stretched along the X axis (blue lines). In both synergistic and suppressive drug combinations, this geometric scaling generates a region between the susceptible and resistant isoboles where only resistant mutants grow (R). In contrast, the suppressive combination also contains a region (S) where the reduced level of drug X experienced by X-resistant strains is less inhibitory, but also less protective from even greater inhibition by drug Y. In such a region, the drugs, administered together, only support growth of the X-susceptible strain, while preventing growth of the resistant strain, and selection for resistance is reversed.<sup>29</sup>


follow. In the schematics in Figures 3 and 4, these more complex effects of resistance mutations are not displayed. Although such factors should be included in a treatment strategy, this simplified two-drug environment presents an exciting potential for a dual treatment strategy using combination chemotherapy to treat an infection, while simultaneously selecting for more treatable, antibiotic-susceptible bacteria.

In addition to their potential to reverse evolution of resistance by imposing selective pressure, suppressive drug combinations can create lower rates of adaptation to antibiotics compared with adaptation rates under synergistic combination treatments. When populations of *Escherichia coli* were subjected to the same synergistic and suppressive drug combinations used in Chait *et al.*<sup>29</sup> the rate of adaptation was observed to be greater under the synergistic pair than under the suppressive pair or indeed under either of the two drugs alone.<sup>45</sup> In order to better understand this effect, the growth rate of *E. coli* under two drug pairs (ciprofloxacin+amikacin and doxycycline+amikacin) and multiple concentrations per drug pair, whose classifications range from antagonism to synergy depending on the dose level,<sup>45</sup> was measured. Intriguingly, a significant positive correlation was found between the rate of adaptation and degree of synergy between the drugs,<sup>45</sup> suggesting the enhanced effect of synergistic combinations comes also with an enhanced risk. This observation further underscores the importance of evaluating not only the direct inhibitory impact of a drug combination on a strain, but also the sign and intensity of selection it imposes on that strain relative to others with altered susceptibility.

Consideration of the above factors underscores the complexity in optimizing treatment strategies. The selective advantage of resistant cells under synergistic drug combinations may lead resistant mutants to outcompete susceptible cells and accumulate further resistance mutations more quickly than under antagonistic or suppressive combinations.<sup>45</sup> Although this suggests that using antagonistic or suppressive drug pairs can slow the rate at which bacteria increase their resistance to antibiotics, it is important to note that the drug comparisons in this study were conducted at roughly equal levels of inhibition.<sup>45</sup> In other scenarios, more efficient killing by synergistic drug pairs could also provide a means to slow the evolution of resistant mutants.<sup>63</sup> Practically, effectively using drug combinations to cure infections while also reducing the threat of resistance may necessitate monitoring factors besides selection, such as population size, ecological carrying capacity and mutational potential.<sup>63</sup>

We can further understand the trade-off between efficacy of inhibition and likelihood to evolve resistance by examining the mutant selection window, which measures the range of drug concentrations above the MIC, where wild-type cells cease to measurably grow, and below the mutant prevention concentration, where no mutant survival is measured.<sup>64</sup> As shown in Figure 4, synergistic drug pairs have larger mutant selection windows than either of the individual constituents, and antagonistic and suppressive drug pairs have smaller mutant selection windows, as they have larger combined MICs than synergistic drug pairs.<sup>39</sup> This simple model adds to the suggestion that there are trade-offs between efficacy of inhibition and likelihood of resistance evolution.

Increased efficacy can be a poor long-term decision if the initial dose of drugs does not kill the entire population. This is because resistant mutants are enriched as drugs decay over time and, ultimately, the most aggressive and potent treatments can end up yielding the highest density of bacteria.<sup>65</sup> In a study by Pena-Miller *et al.*,<sup>65</sup> when bacteria were initially treated with the strongest synergistic drug combinations, remaining bacteria were



**Figure 4** Suppressive drug combinations may have smaller mutant selection windows (MSWs) compared with synergistic combinations. Consider a bacterial population with three subpopulations characterized by MIC isoboles: the wild-type (solid line), a mutant population resistant only to drug X (dashed line), and a mutant population resistant only to drug Y (dotted line). In this simple scenario, without double mutants or cross-resistance, one mutation renders resistance to only drug X and another mutation B renders resistance to only drug Y. The mutant prevention concentration (MPC) line is shown by the outermost isobole, and the MSW is shown by the shaded area between the outermost and innermost isoboles. The MSW is larger in the synergistic combination than in the suppressive combination.

resistant to the drug combination and thus the population subsequently grew at a faster rate in days 2 through 5, compared with when the population was initially treated by just a single drug or a weaker synergistic combination. This finding is consistent with results on the rate of adaptation described earlier,<sup>45</sup> in which synergy yields faster rates of adaptation.

### MECHANISMS OF SUPPRESSION

Understanding how two-drug interactions occur mechanistically may yield valuable insights that could lead to new ways to manipulate cellular growth in clinical settings. This has been especially true of synergistic interactions, where the hope is to create rational combinations with maximum killing effect. The underlying mechanisms of these interactions are likely diverse; yet, even for synergistic interactions the number of discoveries has been limited.<sup>66</sup> Much less is known about mechanisms behind suppressive and antagonistic interactions; probably due to the same reason, there is a bias towards reporting synergy in the literature: thinking that suppressive/antagonistic mechanisms are either outliers or clinically irrelevant. Below we detail several types of mechanisms for suppression/antagonism.


**Bacteriostatic–bactericidal.** A prevalent mechanism of antibiotic antagonism is found in the interaction between bacteriostatic and bactericidal antibiotics, which halt cellular growth and kill growing cells, respectively.<sup>67</sup> When resistance to the bacteriostatic agent restores growth, the resistant strain lies exposed to the second, bactericidal, stress and is eliminated. The quiescent, susceptible strain experiences the reduced effect of the antagonistic combination and survives, thus creating an evolutionary advantage for susceptibility.<sup>67–72</sup> Although it would be useful to check bacteriostatic–bactericidal combinations for suppression, simply combining drugs based on their -static or -cidal effects does not necessarily yield similar phenotypic effects (for example, trimethoprim (bacteriostatic) and streptomycin (bactericidal) are synergistic, not antagonistic<sup>24</sup>).

**Cellular physiology.** Antibiotic interactions can be studied from Fraser’s perspective, in that they result from interfering effects of each of the individual substances on the cells’ physiology. Gene-expression patterns in bacteria subjected to the known suppressive combination

of DNA synthesis inhibitors (for example, ciprofloxacin and nalidixic acid) and protein synthesis inhibitors (for example, spiramycin and tetracycline),<sup>24,29</sup> revealed insight into how bacteria regulate their behavior non-optimally under varying circumstances.<sup>44</sup> In the absence of antibiotics, synthesis rates of the different compartments of the cell (for example, DNA, protein and cell wall) are balanced to produce rapid growth. In the presence of DNA replication inhibitors, such as ciprofloxacin, protein synthesis is not adequately downregulated, causing an imbalance in the ratio of DNA to protein. The addition of a translation-inhibiting drug, spiramycin, can force down the rate of protein synthesis and thus artificially restore the ratio of DNA to protein to a closer to optimal value, enabling the population to grow faster under the combination of both drugs than ciprofloxacin alone. Thus, it was observed that certain suppressive antibiotic interactions find their origins in the non-optimal cross-regulation of the cellular DNA and protein synthesis processes<sup>44</sup> (Figure 5).

Understanding the suppressive interaction in the context of physiological consequences of these two antibiotics’ activity has two notable results. First, suppression may be somewhat robust to the precise antibiotics used (and their particular target sites), provided that one mainly inhibits DNA synthesis and the other protein translation. Similarly, as diverse mechanisms of antibiotic resistance commonly reduce effective antibiotic concentrations upstream of their targets without altering downstream physiology, the interaction may also be somewhat robust to resistance mechanism. In contrast to mechanism-dependent selection against resistance such as seen with collateral sensitivity (susceptibility),<sup>73</sup> resistance mechanism independence has been seen in assays of selection against efflux-, drug degradation- and target-site modification-mediated tetracycline resistance by suppressive ciprofloxacin–doxycycline combinations.<sup>29,40</sup>

**Unknown mechanisms.** Other instances of suppression have been found but the mechanisms are currently unclear. A recent study demonstrated that colistin can essentially suppress vancomycin by enabling methicillin-resistant *Staphylococcus aureus* to survive in vancomycin-enriched environments. Although the exact mechanism is unknown, gene expression changes in methicillin-resistant *Staphylococcus aureus* in the presence of colistin resemble the changes seen in mutant strains that are resistant to vancomycin.<sup>46</sup> Both cases



**Figure 5** A mechanism of suppression between DNA-synthesis inhibitors and protein-synthesis inhibitors. When a DNA-synthesis inhibitor and a protein-synthesis inhibitor are used in combination, the result can be a suppressive interaction.<sup>44</sup> In **a**, this interaction is shown by its outermost isobole and the fitness of the bacteria greatly increases when both Drug X and Drug Y are in high concentration, because the bacteria experience a combined effect less than one or both of the drugs in the combination (**a**). However, when this same drug combination is given to a population of bacteria with genetically reduced level of ribosome synthesis, the suppression disappears (**b**), as shown by an outermost isobole in which increasing the concentration of both Drug X and Drug Y swiftly decreases the bacterial fitness. In populations of genetically manipulated bacteria that overproduce ribosomes, the suppression intensifies (**c**), as shown by an outermost isobole in which increasing the concentration of both Drug X and Drug Y results in an even bigger increase in fitness than in (**a**). Bollenbach *et al.*<sup>44</sup> show that a mismatch in the amount of DNA and ribosomes produced in a cell can more effectively hamper population growth when compared with an overall decrease in both DNA and ribosome production.

involved the GraRS regulon, a two-component regulatory system that is involved in bacterial response to cationic antimicrobial peptides.<sup>46</sup>

Drug interactions may also be sensitive to changes in the genotype of the organism. A large screen of antibiotic interaction mechanisms based on systematic analysis of dose effects in *E. coli* knockout strains found that most genetic perturbations do not affect drug interactions.<sup>47</sup> However, some specific instances of suppression could be amplified, altered, synthetically created or removed, based on certain genetic perturbations.<sup>47</sup> For example, perturbing tRNA processing consistently removed chloramphenicol–nitrofurantoin suppression, ribosome production and assembly altered ciprofloxacin–tetracycline suppression, chaperone deletions consistently caused suppression for distinct drug pairs and perturbing amino acid synthesis amplified chloramphenicol–nitrofurantoin suppression but removed trimethoprim–chloramphenicol antagonism. In particular, polysaccharide synthesis affected the majority of drug interactions, and inhibiting ATP synthase affected the way in which *E. coli* reacted to many different drugs. These findings suggest that only a few recurring cellular functions control multiple drug interactions.<sup>47</sup> Further study is needed to understand why this is so.

Lipopolysaccharide and ATP synthase inhibition are mechanistically interesting, because although lipopolysaccharide and ATP synthesis are central cellular functions, they are not common antibiotic targets. Lipopolysaccharide removal leads to regulated changes in cell composition, affecting drug uptake and proving to be an underlying

mechanism of chloramphenicol–nitrofurantoin suppression and other interactions.<sup>47</sup> ATP-dependent processes such as DNA repair and synthesis are likely the growth-limiting process of bacteria with decreased ATP concentrations in the presence of DNA synthesis inhibitors and inhibiting more than one of these processes can lead to suppression, as discussed by Bollenbach *et al.*<sup>44</sup>

Understanding these mechanisms of suppression and means of altering them could prove useful in clinical treatments. The removal of chloramphenicol–nitrofurantoin suppression by lipopolysaccharide synthesis inhibitors could increase the combination's killing efficacy while preserving its advantages as an unused drug combination.<sup>47</sup> Similarly, the use of thiamin synthesis inhibitors can make the chloramphenicol–trimethoprim combination reciprocally suppressive.<sup>47</sup> This type of suppression, where a drug combination is less inhibitory than either of its individual components, has hardly been found among antibiotics, but could potentially make the path to multidrug resistance even harder by selecting against resistance to both drugs.<sup>29</sup>

#### SUPPRESSION IN NON-ANTIBACTERIAL CONTEXTS

Antagonism and suppression have been found in many non-antibacterial contexts, including genetic interactions,<sup>74</sup> antifungal drugs,<sup>37,75</sup> HIV drugs,<sup>76</sup> metal stress,<sup>77</sup> biocontrol agents,<sup>78</sup> enzyme modifiers,<sup>79</sup> plant defense compounds<sup>52</sup> and antimalarial drugs.<sup>50</sup> In a study that assayed drug interactions within a set of 175 anti-fungal

drug pairs, a large number of suppressive combinations (17%) was found, indicating that suppression (at least in antifungal drug sets) is much more common than previously thought. Interestingly, there were suppression 'hubs' where certain drugs were much more likely to suppress a large number of other drugs. The investigators also found 17 reciprocally suppressive interactions.<sup>25</sup>

A few potential mechanisms of suppression in non-antibiotic contexts have been suggested.<sup>25,80,81</sup> In antifungal research, suppressive combinations have also been shown to select against resistance.<sup>82,83</sup> Mechanisms explaining the tendency of staurosporine to be suppressed and of bromopyruvate to act as a suppressor have been proposed.<sup>25</sup> Staurosporine is an ATP-competitive kinase inhibitor and bromopyruvate acts by inhibiting the glycolysis pathway. Bromopyruvate may be a strong suppressor of staurosporine and other drugs, because it causes media acidification, modifying the cellular concentration of suppressed drugs by affecting drug transporters.<sup>25</sup> However, as with all explanations of the mechanisms dictating suppression, we must be careful about extrapolating to *in vivo* situations. Media acidification and similar effects may be phenomena only observed *in vitro*, thus further highlighting the many difficulties in translating *in vitro* results to *in vivo* situations.

There has been research on other aspects of suppressive interactions in non-antibacterial systems, such as cancer. In a tumor setting, cell cycle-dependent antagonistic effects, where one drug prevents entry of cells into a phase in which the other drug is more effective, have been found between taxol and  $\gamma$ -radiation,<sup>84</sup> cisplatin and the antimicrotubule agents taxol and vincristine,<sup>85</sup> and novel anti-HER2 monoclonal antibodies and tumor necrosis factor- $\alpha$ .<sup>86</sup> Cell cycle-dependent antagonisms in cancer treatment<sup>84,86</sup> suggest that cell cycle-dependent phenomena may be a rich avenue for investigating suppressive interactions. Selection against resistant tumor cells due to the suppressive drug combination of doxorubicin and taxol has been shown.<sup>87</sup>

Furthermore, the exploration of higher-order (more than two component) drug combinations in different systems may reveal different patterns of interactions and levels of antagonism and suppression. Wood *et al.*<sup>88</sup> found that higher-order drug combinations yielded primarily additive interactions. However, re-scaling produced a multi-modal distribution from which more synergistic and antagonistic interactions could be straightforwardly identified.<sup>53</sup> Furthermore, when examining emergent interactions in higher-order combinations, that is, interactions that rely on all three drugs being present rather than the interaction primarily being the result of interactions between only two of the three drugs, it appears that emergent interactions may be skewed towards increasing antagonism.<sup>53,89</sup> Identification and classification of higher-order interactions is an exciting current area of research due to the important distinction between net (overall) and emergent interactions,<sup>89</sup> the multiple classification systems already existing at the pairwise level<sup>27</sup> and considerable debate about whether higher-order interactions need to be considered at all or whether pairwise interactions are sufficient to predict the overall behavior of complex systems.<sup>90,91</sup>

Prevalence of suppressive interactions varies greatly depending on the elements tested, model used, and classification method. Although we know that suppressive interactions are rarely reported in the antibiotic literature, they made up ~9% of interactions in a study of a complete pairwise interaction network between 21 drugs.<sup>24</sup> Studies have found other systems have higher, yet also varied, rates of suppression.<sup>25,37,78,92</sup> Antagonistic interactions have been observed to be more common than synergistic interactions among biological

control agents (living organisms used to control threats to agriculture)<sup>78</sup> and herbicides,<sup>80</sup> although reasons for this are unclear.

## USE OF SUPPRESSIVE DRUG COMBINATIONS IN THE CLINIC

Using suppressive drug combinations to combat drug resistance in the clinic presents significant challenges. Living systems are much more complex than *in vitro* systems due to factors such as differential degradation of drugs,<sup>11</sup> the role of the immune system in selecting for resistant bacteria<sup>93</sup> and the increased efficacy of bacteriostatic agents.<sup>94</sup> To our knowledge, all studies demonstrating the potential of suppressive drug combinations to reverse evolution of resistance have been performed *in vitro* or *in silico*.

Using suppressive drug combinations *in vivo* likely represents a trade-off between killing efficacy and likelihood of future evolution of resistance.<sup>15,39</sup> Even if suppressive regimens work perfectly, we must consider the fundamental issue that therapies are most often designed to treat the individual, but what is in the best interest of the individual may not always be good for the public at large.<sup>95</sup> The increased dosages required in suppressive combinations could increase the risk of toxic side effects to the patient (especially for the case of bactericidal drugs), yet there may be benefits to the general population in terms of reduced risk of resistance evolution.

When strong selection for resistance is generated by a combined antibiotic treatment (for example, for synergistic combinations) and resistance evolves, the cost of more effective individual treatment is borne by the public in the form of long-term loss of treatment options and more recalcitrant future infections. Suppressive combinations would present a cost to the individual (higher doses of drugs, with potentially more toxicity, to achieve the same rate of infection clearance), but would also benefit the public at large by reducing the level of resistance and maintaining more treatable infections for the future. Therefore, the use of both suppressive and synergistic drug combinations should take into account both the specific public and individual interests involved in a specific infection and environment. For instance, toxicity allowing, a suppressive drug combination may potentially be useful in the case of TB<sup>96</sup> and other scenarios in which antibiotics are used in widespread, long-term therapy and the emergence of resistance is a major threat to both active patients and the public.<sup>97</sup>

A dynamic treatment protocol that uses both suppressive combinations (or other tactics to give susceptible bacteria a selective advantage) and regular antibiotic treatment may be a solution that could maximize killing efficacy while minimizing resistance.<sup>97</sup> Recent mathematical work compares growth of susceptible and resistant bacteria under different conditions and demonstrates how a precisely timed combination of treatments can select for susceptibility. In the model used, a costly plasmid confers antibiotic resistance.<sup>97</sup> The work suggests that the optimal amount of time to apply suppressive combinations to a resistant population until an antibiotic treatment is effective depends on three main factors: the pathogen division rate, the rate of plasmid loss and the difference in growth rate between susceptible and resistant strains.<sup>97</sup> As the optimal strategy changes as the bacterial population changes, we must further understand under exactly which conditions to apply which treatment and how to quickly and cheaply monitor these conditions to appropriately schedule such treatments of bacterial infections.<sup>15</sup>

We can better understand how the composition of a bacterial infection affects treatment strategies by considering a computational infection model that takes into account the overall strength of the drug-drug interaction and the relative and absolute numbers of susceptible and resistant subpopulations competing for a limited

supply of nutrients.<sup>63</sup> In the absence of any resource competition, highly effective synergistic drug pairs represent the optimal treatment, rapidly eliminating infections and thus best preventing the prolonged cycles of division and mutation that allow resistance to the combination to evolve.

However, when the bacteria exist in a milieu in which they must compete for resources, the picture changes dramatically: if a synergistic drug pair is applied, the resources freed by the rapid removal of the susceptible strain allows a strain that has become resistant to one of the antibiotics to grow and mutate to resist both drugs much more rapidly, while it is still present in large numbers. On the other hand, if a suppressive drug combination is used, the susceptible bacteria are killed much more slowly than the single-drug resistant cells.<sup>63</sup> Although the single-drug resistant population is being killed, the overall infection remains sufficiently large such that nutrient limitation suppresses growth and thus slows generation of novel mutations in the singly resistant subpopulation. Once only susceptible bacteria are left in this (still relatively large) population, it can be cleared with a single antibiotic or synergistic drug combination. In this model, synergistic drug combinations rapidly eliminate the infection but can increase the risk of generating mutants that are entirely resistant to the drug combination, whereas antagonistic or suppressive drug pairs are less effective at removing the infection but are typically less likely to produce conditions favorable to the evolution of doubly resistant mutants.<sup>63</sup> As noted above, certain cases also exist where a synergistic combination better prevents mutations and the emergence of resistance, contingent on the specific ecology of the infection.<sup>63</sup>

Although some researchers have advocated for this more ecology-centric approach to the problem of drug resistance,<sup>97–100</sup> there are many challenges to taking this approach. These include determining the extent to which resource competition has a role in such a complex environment as the patient's body<sup>98</sup> and obtaining accurate parameters of traits that determine resource competition in the human body,<sup>98</sup> including nutrient availability in various sites of infection.<sup>101</sup>

Another difficulty with using suppressive drug combinations is that physiological interactions can change across different environments and genetic backgrounds or as pathogens evolve.<sup>15</sup> In addition, there are only narrow windows of drug concentrations for which these strategies have been shown to work,<sup>29</sup> and different factors such as time since last dose<sup>102</sup> and the tissue being targeted<sup>103</sup> can change the intended effects of drugs in the body. Of particular concern, it has been found that even a weak antagonistic interaction leads to a very dynamic optimal treatment protocol<sup>104</sup> due to the changing resistance profile of the infection continuously redefining the efficacy of chosen treatment strategies.<sup>29</sup> Tailoring treatments to take into account dynamic bacterial resistance profiles and factors that affect the strength and type of physiological interactions presents a major area for further study.

## FUTURE DIRECTIONS

Although suppressive drug combinations are one of only a few potential strategies to combat emergence of resistance, their effects on treatment efficacy and resistance prevention are likely to be affected by a number of factors and there is a long way to go before they can be used clinically. We have identified five research directions as especially pressing: (1) technological advances and/or high-throughput screening methods to more efficiently identify suppression; (2) further identification of suppressive mechanisms of action; (3) examination of other factors (for example, type of bacteria and dose dependence) that can affect suppressive interactions; (4) investigation of the ecological role that resource competition could have in treatment; and (5) *in vivo*

studies to better understand the effects of suppressive interactions in the body.

Even with new technologies, we cannot simply test all drug combinations for suppression—given the large numbers of drug combinations, this would be logistically difficult.<sup>105</sup> We need to search for more efficient ways to identify suppression, such as conducting screens to discover if the types of suppression hubs found in antifungal drug screenings<sup>25</sup> also exist in antibiotic networks. Suppression often cannot be predicted based on mechanisms of action,<sup>62</sup> but continuing to identify suppressive mechanisms of action may lead to the discovery of generalized suppression between certain drug classes, such as DNA synthesis inhibitors and protein synthesis inhibitors.<sup>44</sup>

Other factors, such as how adding a third component to a pairwise suppressive combination can increase the magnitude of suppression or create a reciprocally suppressive combination,<sup>53,106</sup> should also be investigated. It is also of interest to understand the effect of type of bacteria on observed interaction type<sup>60,61</sup> and to conduct careful dose-dependent tests *in vitro*, to establish a clearer idea of what concentrations are suppressive and how wide or narrow this range is.

In addition, there needs to be careful examination of whether and how different ecological components of resource competition are relevant to treatment using suppression. For example, it would be useful to understand the extent to which different parameters affect resource competition, and whether resource competition could be exploited clinically through the use of dynamic treatment protocols or the introduction of drug-susceptible non-pathogenic strains.<sup>63,97</sup> These factors may affect the number and magnitude of suppressive combinations.

Ultimately, basic *in vivo* studies must be conducted to determine whether the results of *in vitro* and *in silico* experiments hold when treating infections, as well as to more explicitly identify the potential risks and complications of using suppressive drug combinations in treatment. After conducting careful dose-dependence tests *in vitro*, the next key step in translating suppressive combinations to the clinic would be testing suppressive combinations in animal models to establish better understanding of risks as well as necessary concentrations, pharmacodynamics and pharmacokinetics.<sup>107</sup> These tests would also help us understand how quickly resistance profiles of bacterial populations change in response to suppressive drugs *in vivo*. This would in turn inform the timing of switches from suppressive to synergistic or classic antibiotic treatment once most of the resistant bacteria have been killed.<sup>97</sup>

If suppressive drug combinations show *in vivo* potential in animal models, a first case in which to use them clinically may be in the treatment of diseases like TB.<sup>96</sup> As TB requires long-term treatment, the patient receiving the suppressive drug treatment would be able to reap the benefits of reversal of resistance, rather than only the general public benefiting from the likely more toxic and higher dosage suppressive treatment regimen.

The properties of antagonistic and suppressive drug combinations to slow or even reverse the evolution of increasing drug resistance suggest intriguing clinical potential. However, as we have noted, there are a great many exigencies, which desperately require more studies (particularly *in vivo*), to clarify whether real cases for use exist. Given our diminishing options to treat increasingly resistant pathogens and the critical need to protect available treatment options, we suggest that the long known, yet underappreciated, suppressive interactions are a worthy research direction to pursue.

## CONFLICT OF INTEREST

The authors declare no conflict of interest.



## ACKNOWLEDGEMENTS

This research was supported by NIH/National Center for Advancing Translational Science (NCATS) UCLA CTSI Grant Number UL1TR001881. We thank Remy Chait, Jeffrey H. Miller, Lei Dai, Casey Beppler and Roy Kishony for discussion and/or comments on the manuscript.

- 1 Taubes, G. The bacteria fight back. *Science* **321**, 356–361 (2008).
- 2 Levy, S. B. *The Antibiotic Paradox: How the Misuse of Antibiotics Destroys Their Curative Powers* (Perseus Publishing, USA, 2002).
- 3 Lewis, K, Salyers, A, Taber, H & Wax, R. *Bacterial Resistance to Antimicrobials: Mechanisms, Genetics, Medical Practice and Public Health* (Marcel Dekker, New York, 2001).
- 4 Koul, A., Arnoult, E., Lounis, N., Guillemont, J. & Andries, K. The challenge of new drug discovery for tuberculosis. *Nature* **469**, 483–490 (2011).
- 5 Clardy, J., Fischbach, M. A. & Walsh, C. T. New antibiotics from bacterial natural products. *Nat. Biotechnol.* **24**, 1541–1550 (2006).
- 6 Devasahayam, G., Scheld, W. M. & Hoffman, P. S. Newer antibacterial drugs for a new century. *Expert Opin. Invest. Drugs* **19**, 215–234 (2010).
- 7 Drawz, S. M. & Bonomo, R. A. Three decades of  $\beta$ -lactamase inhibitors. *Clin. Microbiol. Rev.* **23**, 160–201 (2010).
- 8 Stone, L. K., Baym, M., Lieberman, T. D., Chait, R., Clardy, J. & Kishony, R. Compounds that select against the tetracycline-resistance efflux pump. *Nat. Chem. Biol.* **12**, 902–904 (2016).
- 9 Everitt, E., Han, E., Cherian, S., Kempf, D., Sham, H. & Ng, S.-C. Compositions and methods for enhancing the bioavailability of pharmaceutical agents. *Google Patents* (2002).
- 10 Ali, B. Agents ameliorating or augmenting experimental gentamicin nephrotoxicity: some recent research. *Food Chem. Toxicol.* **41**, 1447–1452 (2003).
- 11 Roberts, J. A. *et al.* Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions. *Lancet Infect. Dis.* **14**, 498–509 (2014).
- 12 Boucher, H. W. *et al.* Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. *Clin. Infect. Dis.* **48**, 1–12 (2009).
- 13 Perry, J. A. The antibiotic resistome: what's new? *Curr. Opin. Biol.* **21**, 45–50 (2014).
- 14 Boeckel, T. P. V. *et al.* Global trends in antimicrobial use in food animals. *Proc. Natl Acad. Sci. USA* **112** (2015).
- 15 Baym, M., Stone, L. K. & Kishony, R. Multidrug evolutionary strategies to reverse antibiotic resistance. *Science* **351**, aad3292 (2016).
- 16 Smith, D. L., Harris, A. D., Johnson, J. A., Silbergeld, E. K. & Morris, J. G. Animal antibiotic use has an early but important impact on the emergence of antibiotic resistance in human commensal bacteria. *Proc. Natl Acad. Sci. USA* **99**, 6434–6439 (2002).
- 17 Stone, G. W. *et al.* Mechanism of action of NB2001 and NB2030, novel antibacterial agents activated by  $\beta$ -lactamases. *Antimicrob. Agents Chemother.* **48**, 477–483 (2004).
- 18 Munck, C., Gumpert, H. K., Wallin, A. I. N., Wang, H. H. & Sommer, M. O. Prediction of resistance development against drug combinations by collateral responses to component drugs. *Sci. Transl. Med.* **6**, 262ra156–262ra156 (2014).
- 19 Shafer, R. & Vuitton, D. Highly active antiretroviral therapy (HAART) for the treatment of infection with human immunodeficiency virus type 1. *Biomed. Pharmacother.* **53**, 73–86 (1999).
- 20 Ramón-García, S. *et al.* Synergistic drug combinations for tuberculosis therapy identified by a novel high-throughput screen. *Antimicrob. Agents Chemother.* **55**, 3861–3869 (2011).
- 21 Bozic, I. *et al.* Evolutionary dynamics of cancer in response to targeted combination therapy. *eLife* **2** (2013).
- 22 Keith, C. T., Borisy, A. A. & Stockwell, B. R. Multicomponent therapeutics for networked systems. *Nat. Rev. Drug Discov.* **4**, 71–78 (2005).
- 23 Braberg, H. *et al.* Quantitative analysis of triple-mutant genetic interactions. *Nat. Protoc.* **9**, 1867–1881 (2014).
- 24 Yeh, P., Tschumi, A. I. & Kishony, R. Functional classification of drugs by properties of their pairwise interactions. *Nat. Genet.* **38**, 489–494 (2006).
- 25 Cokol, M. *et al.* Large-scale identification and analysis of suppressive drug interactions. *Chem. Biol.* **21**, 541–551 (2014).
- 26 Lepper, M. H. & Dowling, H. F. Treatment of pneumococcal meningitis with penicillin compared with penicillin plus aureomycin: studies including observations on an apparent antagonism between penicillin and aureomycin. *AMA Arch. Int. Med.* **88**, 489–494 (1951).
- 27 Fouquier, J. & Guedj, M. Analysis of drug combinations: current methodological landscape. *Pharmacol. Res. Perspect.* **3** (2015).
- 28 Bliss, C. The toxicity of poisons applied jointly. *Ann. Appl. Biol.* **26**, 585–615 (1939).
- 29 Chait, R., Craney, A. & Kishony, R. Antibiotic interactions that select against resistance. *Nature* **446**, 668–671 (2007).
- 30 Fraser, T. R. Lecture on the antagonism between the actions of active substances. *Br. Med. J.* **2**, 457 (1872).
- 31 Fraser, T. R. 5. An experimental research on the antagonism between the actions of physostigma and atropia. *Proc. R. Soc. Edinburgh* **7**, 506–511 (1872).
- 32 Weiss, S. Persistence of action of physostigmin and the atropin-physostigmin antagonism in animals and in man. *J. Pharmacol. Exp. Ther.* **27**, 181–188 (1926).
- 33 Browning, C. & Gulbransen, R. An interference phenomenon in the action of chemotherapeutic substances in experimental trypanosome infections. *J. Pathol. Bacteriol.* **25**, 395–397 (1922).
- 34 Proudfoot, A. The early toxicology of physostigmine. *Toxicol. Rev.* **25**, 99–138 (2006).
- 35 Yeh, P. J., Hegreness, M. J., Aiden, A. P. & Kishony, R. Drug interactions and the evolution of antibiotic resistance. *Nat. Rev. Microbiol.* **7**, 460–466 (2009).
- 36 Yeh, P. & Kishony, R. Networks from drug–drug surfaces. *Mol. Syst. Biol.* **3**, 85 (2007).
- 37 de Vos, M. G. & Bollenbach, T. Suppressive drug interactions between antifungals. *Chem. Biol.* **21**, 439–440 (2014).
- 38 Stechmann, B. *et al.* Inhibition of retrograde transport protects mice from lethal ricin challenge. *Cell* **141**, 231–242 (2010).
- 39 Michel, J.-B., Yeh, P. J., Chait, R., Moellering, R. C. & Kishony, R. Drug interactions modulate the potential for evolution of resistance. *Proc. Natl Acad. Sci. USA* **105**, 14918–14923 (2008).
- 40 Chait, R., Shrestha, S., Shah, A. K., Michel, J.-B. & Kishony, R. A differential drug screen for compounds that select against antibiotic resistance. *PLoS ONE* **5**, e15179 (2010).
- 41 Cokol, M. *et al.* Systematic exploration of synergistic drug pairs. *Mol. Syst. Biol.* **7**, 544 (2011).
- 42 Mitosch, K. & Bollenbach, T. Bacterial responses to antibiotics and their combinations. *Environ. Microbiol. Rep.* **6**, 545–557 (2014).
- 43 Palmer, A. C. & Kishony, R. Opposing effects of target overexpression reveal drug mechanisms. *Nat. Commun.* **5**, 4296 (2014).
- 44 Bollenbach, T., Quan, S., Chait, R. & Kishony, R. Nonoptimal microbial response to antibiotics underlies suppressive drug interactions. *Cell* **139**, 707–718 (2009).
- 45 Hegreness, M., Shores, N., Damian, D., Hartl, D. & Kishony, R. Accelerated evolution of resistance in multidrug environments. *Proc. Natl Acad. Sci. USA* **105**, 13977–13981 (2008).
- 46 Haaber, J., Friberg, C., McCreary, M., Lin, R., Cohen, S. N. & Ingmer, H. Reversible antibiotic tolerance induced in *Staphylococcus aureus* by concurrent drug exposure. *Mbio* **6**, e02268–e03214 (2015).
- 47 Chevereau, G. & Bollenbach, T. Systematic discovery of drug interaction mechanisms. *Mol. Syst. Biol.* **11**, 807 (2015).
- 48 Motter, A. E. Improved network performance via antagonism: from synthetic rescues to multi-drug combinations. *Bioessays* **32**, 236–245 (2010).
- 49 Berenbaum, M. Synergy, additivism and antagonism in immunosuppression. A critical review. *Clin. Exp. Immunol.* **28**, 1 (1977).
- 50 Bell, A. Antimalarial drug synergism and antagonism: mechanistic and clinical significance. *FEMS Microbiol. Lett.* **253**, 171–184 (2005).
- 51 Geary, N. Understanding synergy. *Am. J. Physiol. Endocrinol. Metab.* **304**, E237–E253 (2013).
- 52 Nelson, A. C. & Kursar, T. A. Interactions among plant defense compounds: a method for analysis. *Chemoecology* **9**, 81–92 (1999).
- 53 Tekin, E., Beppler, C., White, C., Mao, Z., Savage, V. M. & Yeh, P. J. Enhanced identification of synergistic and antagonistic emergent interactions among three or more drugs. *J. R. Soc. Interface* **13**, 20160332 (2016).
- 54 Zhou, A. *et al.* Synergistic interactions of vancomycin with different antibiotics against *Escherichia coli*: trimethoprim and nitrofurantoin display strong synergies with vancomycin against wild-type *E. coli*. *Antimicrob. Agents Chemother.* **59**, 276–281 (2015).
- 55 Nguyen, C., Zhou, A., Khan, A., Miller, J. H. & Yeh, P. Pairwise antibiotic interactions in *Escherichia coli*: triclosan, rifampicin and aztreonam with nine other classes of antibiotics. *J. Antibiot.* **69**, 791–797 (2016).
- 56 Jia, J., Zhu, F., Ma, X., Cao, Z. W., Li, Y. X. & Chen, Y. Z. Mechanisms of drug combinations: interaction and network perspectives. *Nat. Rev. Drug Discov.* **8**, 111–128 (2009).
- 57 Osborne, C. K., Kitten, L. & Arteaga, C. L. Antagonism of chemotherapy-induced cytotoxicity for human breast cancer cells by antiestrogens. *J. Clin. Oncol.* **7**, 710–717 (1989).
- 58 French, G. L., Ling, T. K., Davies, D. P. & Leung, D. T. Antagonism of ceftazidime by chloramphenicol *in vitro* and *in vivo* during treatment of gram negative meningitis. *Br. Med. J. (Clin. Res. Ed.)* **291**, 636–637 (1985).
- 59 Jonker, D. M., Visser, S. A. G., van der Graaf, Piet, H., Voskuyl, R. A. & Danhof, M. Towards a mechanism-based analysis of pharmacodynamic drug–drug interactions *in vivo*. *Pharmacol. Ther.* **106**, 1–18 (2005).
- 60 Jacqueline, C. *et al.* *In vitro* and *in vivo* synergistic activities of linezolid combined with subinhibitory concentrations of imipenem against methicillin-resistant *Staphylococcus aureus*. *Antimicrob. Agents Chemother.* **49**, 45–51 (2005).
- 61 Wicha, S. G., Kees, M. G., Kuss, J. & Kloft, C. Pharmacodynamic and response surface analysis of linezolid or vancomycin combined with meropenem against *Staphylococcus aureus*. *Pharm. Res.* **32**, 2410–2418 (2015).
- 62 Ankamah, P., Johnson, P. J. & Levin, B. R. The pharmacology, population and evolutionary dynamics of multi-drug therapy: experiments with *S. aureus* and *E. coli* and computer simulations. *PLoS Pathog.* **9**, e1003300 (2013).
- 63 Torella, J. P., Chait, R. & Kishony, R. Optimal drug synergy in antimicrobial treatments. *PLoS Comput. Biol.* **6**, e1000796 (2010).
- 64 Dong, Y., Zhao, X., Domagala, J. & Drlica, K. Effect of fluoroquinolone concentration on selection of resistant mutants of *Mycobacterium bovis* BCG and *Staphylococcus aureus*. *Antimicrob. Agents Chemother.* **43**, 1756–1758 (1999).

- 65 Pena-Miller, R. *et al.* When the most potent combination of antibiotics selects for the greatest bacterial load: the smile-frown transition. *PLoS Biol.* **11**, e1001540 (2013).
- 66 Cottarel, G. & Wierzbowski, J. Combination drugs, an emerging option for antibacterial therapy. *Trends Biotechnol.* **25**, 547–555 (2007).
- 67 Ocampo, P. S. *et al.* Antagonism between bacteriostatic and bactericidal antibiotics is prevalent. *Antimicrob. Agents Chemother.* **58**, 4573–4582 (2014).
- 68 Dance, D., Wuthiekanun, V., Chaowagul, W. & White, N. Interactions in vitro between agents used to treat melioidosis. *J. Antimicrob. Chemother.* **24**, 311–316 (1989).
- 69 Davis, B. D. Isolation of biochemically deficient mutants of bacteria by penicillin. *J. Am. Chem. Soc.* **70**, 4267–4267 (1948).
- 70 Tuomanen, E., Cozens, R., Tosch, W., Zak, O. & Tomasz, A. The rate of killing of *Escherichia coli* by  $\beta$ -lactam antibiotics is strictly proportional to the rate of bacterial growth. *Microbiology* **132**, 1297–1304 (1986).
- 71 Balaban, N. Q., Merrin, J., Chait, R., Kowalik, L. & Leibler, S. Bacterial persistence as a phenotypic switch. *Science* **305**, 1622–1625 (2004).
- 72 Hall-Stoodley, L., Costerton, J. W. & Stoodley, P. Bacterial biofilms: from the natural environment to infectious diseases. *Nat. Rev. Microbiol.* **2**, 95–108 (2004).
- 73 Li, Q. *et al.* NB2001, a novel antibacterial agent with broad-spectrum activity and enhanced potency against  $\beta$ -lactamase-producing strains. *Antimicrob. Agents Chemother.* **46**, 1262–1268 (2002).
- 74 MacLean, R. C., Hall, A. R., Perron, G. G. & Buckling, A. The population genetics of antibiotic resistance: integrating molecular mechanisms and treatment contexts. *Nat. Rev. Genet.* **11**, 405–414 (2010).
- 75 Anderson, J. B., Ricker, N. & Sirjusingh, C. Antagonism between two mechanisms of antifungal drug resistance. *Eukaryot. Cell* **5**, 1243–1251 (2006).
- 76 Bretscher, M. T., Althaus, C. L., Müller, V. & Bonhoeffer, S. Recombination in HIV and the evolution of drug resistance: for better or for worse? *Bioessays* **26**, 180–188 (2004).
- 77 Taylor, G. J., Stadt, K. J. & Dale, M. R. Modelling the interactive effects of aluminum, cadmium, manganese, nickel and zinc stress using the Weibull frequency distribution. *Environ. Exp. Botany* **32**, 281–293 (1992).
- 78 Xu, X.-M., Jeffries, P., Pautasso, M. & Jeger, M. J. Combined use of biocontrol agents to manage plant diseases in theory and practice. *Phytopathology* **101**, 1024–1031 (2011).
- 79 Schenker, P. & Baici, A. Simultaneous interaction of enzymes with two modifiers: reappraisal of kinetic models and new paradigms. *J. Theor. Biol.* **261**, 318–329 (2009).
- 80 Cedergreen, N., Kudsk, P., Mathiassen, S. K. & Streibig, J. C. Combination effects of herbicides on plants and algae: do species and test systems matter? *Pest Manag. Sci.* **63**, 282–295 (2007).
- 81 Farha, M. A. *et al.* Antagonism screen for inhibitors of bacterial cell wall biogenesis uncovers an inhibitor of undecaprenyl diphosphate synthase. *Proc. Natl Acad. Sci. USA* **112**, 11048–11053 (2015).
- 82 Cowen, L. E. The evolution of fungal drug resistance: modulating the trajectory from genotype to phenotype. *Nat. Rev. Microbiol.* **6**, 187–198 (2008).
- 83 Anderson, J. B. Evolution of antifungal-drug resistance: mechanisms and pathogen fitness. *Nat. Rev. Microbiol.* **3**, 547–556 (2005).
- 84 Sui, M., Dziadyk, J. M., Zhu, X. & Fan, W. Cell cycle-dependent antagonistic interactions between paclitaxel and  $\gamma$ -radiation in combination therapy. *Clin. Cancer Res.* **10**, 4848–4857 (2004).
- 85 Rowinsky, E. K., Citardi, M. J., Noe, D. A. & Donehower, R. C. Sequence-dependent cytotoxic effects due to combinations of cisplatin and the antimicrotubule agents taxol and vincristine. *J. Cancer Res. Clin. Oncol.* **119**, 727–733 (1993).
- 86 Ceran, C., Cokol, M., Cingoz, S., Tasan, I., Ozturk, M. & Yagci, T. Novel anti-HER2 monoclonal antibodies: synergy and antagonism with tumor necrosis factor- $\alpha$ . *BMC Cancer* **12**, 450 (2012).
- 87 Blagosklonny, M. Drug-resistance enables selective killing of resistant leukemia cells: exploiting of drug resistance instead of reversal. *Leukemia* **13**, 2031–2035 (1999).
- 88 Wood, K., Nishida, S., Sontag, E. D. & Cluzel, P. Mechanism-independent method for predicting response to multidrug combinations in bacteria. *Proc. Natl Acad. Sci. USA* **109**, 12254–12259 (2012).
- 89 Beppler, C. *et al.* Uncovering emergent interactions in three-way combinations of stressors. *J. R. Soc. Interface* **13** (2016).
- 90 Wood, K. B. Pairwise interactions and the battle against combinatorics in multidrug therapies. *Proc. Natl Acad. Sci. USA* **113**, 10231–10233 (2016).
- 91 Tekin, E., Savage, V. M. & Yeh, P. J. Measuring higher-order drug interactions: a review of recent approaches. *Curr. Opin. Syst. Biol.* **4**, 16–23 (2017).
- 92 Steinbach, W. J., Stevens, D. A. & Denning, D. W. Combination and sequential antifungal therapy for invasive aspergillosis: review of published in vitro and in vivo interactions and 6281 clinical cases from 1966 to 2001. *Clin. Infect. Dis.* **37** (Supplement 3), S188–S244 (2003).
- 93 Brandl, K. *et al.* Vancomycin-resistant enterococci exploit antibiotic-induced innate immune deficits. *Nature* **455**, 804–807 (2008).
- 94 Pankey, G. A. & Sabath, L. D. Clinical relevance of bacteriostatic versus bactericidal mechanisms of action in the treatment of Gram-positive bacterial infections. *Clin. Infect. Dis.* **38**, 864–870 (2004).
- 95 Foster, K. R. & Grundmann, H. Do we need to put society first? The potential for tragedy in antimicrobial resistance. *PLoS Med.* **3**, e29 (2006).
- 96 Connolly, L. E., Edelstein, P. H. & Ramakrishnan, L. Why is long-term therapy required to cure tuberculosis? *PLoS Med.* **4**, e120 (2007).
- 97 Gomes, A. L., Galagan, J. E. & Segrè, D. Resource competition may lead to effective treatment of antibiotic resistant infections. *PLoS ONE* **8**, e80775 (2013).
- 98 Day, T., Huijben, S. & Read, A. F. Is selection relevant in the evolutionary emergence of drug resistance? *Trends Microbiol.* **23**, 126–133 (2015).
- 99 Singer, R. S., Ward, M. P. & Maldonado, G. Can landscape ecology untangle the complexity of antibiotic resistance? *Nat. Rev. Microbiol.* **4**, 943–952 (2006).
- 100 Levy, S. B. & Marshall, B. Antibacterial resistance worldwide: causes, challenges and responses. *Nat. Med.* **10**, S122–S129 (2004).
- 101 Smith, V. H. & Holt, R. D. Resource competition and within-host disease dynamics. *Trends Ecol. Evol.* **11**, 386–389 (1996).
- 102 Kano, Y., Ohnuma, T., Okano, T. & Holland, J. F. Effects of vincristine in combination with methotrexate and other antitumor agents in human acute lymphoblastic leukemia cells in culture. *Cancer Res.* **48**, 351–356 (1988).
- 103 Torchilin, V. P. Drug targeting. *Eur. J. Pharm. Sci.* **11**, S81–S91 (2000).
- 104 Orlando, P. A., Gatenby, R. A. & Brown, J. S. Cancer treatment as a game: integrating evolutionary game theory into the optimal control of chemotherapy. *Phys. Biol.* **9**, 065007 (2012).
- 105 Bollenbach, T. Antimicrobial interactions: mechanisms and implications for drug discovery and resistance evolution. *Curr. Opin. Microbiol.* **27**, 1–9 (2015).
- 106 Rodea-Palomares, I., González-Pleiter, M., Martín-Betancor, K., Rosal, R. & Fernández-Piñas, F. Additivity and interactions in ecotoxicity of pollutant mixtures: some patterns, conclusions, and open questions. *Toxics* **3**, 342–369 (2015).
- 107 Beppler, C. *et al.* When more is less: emergent suppressive interactions in three-drug combinations. *BMC Microbiol.* **17**, 107 (2017).
- 108 Loewe, S. The problem of synergism and antagonism of combined drugs. *Arzneimittel-Forschung* **3**, 285 (1953).